Daiwa Securities Group’s Legend Biotech LEGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-254
Closed -$6K 1326
2025
Q4
$6K Hold
254
﹤0.01% 1221
2025
Q3
$8K Sell
254
-40
-14% -$1.48K ﹤0.01% 1170
2025
Q2
$10K Sell
294
-7,432
-96% -$241K ﹤0.01% 1119
2025
Q1
$263K Sell
7,726
-790
-9% -$28.3K ﹤0.01% 905
2024
Q4
$278K Buy
8,516
+5,309
+166% +$220K ﹤0.01% 916
2024
Q3
$156K Sell
3,207
-330
-9% -$17.6K ﹤0.01% 978
2024
Q2
$157K Sell
3,537
-2,822
-44% -$130K ﹤0.01% 997
2024
Q1
$356K Buy
6,359
+527
+9% +$31.8K ﹤0.01% 891
2023
Q4
$351K Buy
5,832
+5,571
+2,134% +$353K ﹤0.01% 880
2023
Q3
$18K Hold
261
﹤0.01% 1101
2023
Q2
$18K Hold
261
﹤0.01% 1108
2023
Q1
$13K Hold
261
﹤0.01% 1096
2022
Q4
$13K Buy
261
+62
+31% +$3K ﹤0.01% 1101
2022
Q3
$8K Hold
199
﹤0.01% 1139
2022
Q2
$11K Sell
199
-4,517
-96% -$191K ﹤0.01% 1139
2022
Q1
$172K Buy
4,716
+2,020
+75% +$79.8K ﹤0.01% 983
2021
Q4
$126K Buy
2,696
+2,587
+2,373% +$131K ﹤0.01% 998
2021
Q3
$6K Buy
109
+69
+173% +$2.87K ﹤0.01% 1169
2021
Q2
$2K Hold
40
﹤0.01% 1143
2021
Q1
$1K Hold
40
﹤0.01% 1210
2020
Q4
$1K Buy
+40
New +$1.15K ﹤0.01% 1187

Other funds holding LEGN

Daiwa Securities Group's LEGN Position: Q1 2026 in Review

Daiwa Securities Group sold out of Legend Biotech (LEGN) in Q1 2026, closing a stake of 254 shares — an estimated $6K sold.

Daiwa Securities Group first reported a position in LEGN in Q4 2020 and held it in 21 quarters. The position peaked at $356K in Q1 2024. 189 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Daiwa Securities Group reported no remaining Legend Biotech position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 254 Legend Biotech shares in Q1 2026, an estimated $6K.
  • Daiwa Securities Group first reported a position in Legend Biotech in Q4 2020 and held it in 21 quarters.
  • Daiwa Securities Group's Legend Biotech position peaked at $356K in Q1 2024.
  • 189 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.